These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 30551367)

  • 21. A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases.
    Chen B; Shi X; Cui Y; Hou A; Zhao P
    Curr Top Med Chem; 2019; 19(20):1790-1817. PubMed ID: 31400268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.
    Alkhalil M
    Curr Drug Metab; 2019; 20(1):72-82. PubMed ID: 30112987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Schulz R; Schlüter KD; Laufs U
    Basic Res Cardiol; 2015 Mar; 110(2):4. PubMed ID: 25600226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
    Filippatos TD; Christopoulou EC; Elisaf MS
    Curr Opin Lipidol; 2018 Aug; 29(4):333-339. PubMed ID: 29994840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCSK9 targets important for lipid metabolism.
    Schulz R; Schlüter KD
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
    Thiery J; Burkhardt R
    Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
    Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A
    Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence.
    Zhu XB; Xu YY; Li LC; Sun JB; Wang YZ; Chen J; Wang C; Zhang S; Jin LY
    Drug Dev Res; 2024 Feb; 85(1):e22131. PubMed ID: 37943623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.
    Kosmas CE; DeJesus E; Morcelo R; Garcia F; Montan PD; Guzman E
    Drugs Context; 2017; 6():212511. PubMed ID: 29209403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.
    Saeed A; Virani SS; Jones PH; Ballantyne CM; Nambi V
    J Clin Lipidol; 2018; 12(5):1141-1145. PubMed ID: 30318064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
    Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
    Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.